Assignee
AMPSOURCE BIOPHARMA SHANGHAI INC
CN·8 granted patents·12 pending applications·9 citations·filing 2016–2024
Top patents by PatentIndex Score
20 records- 0185US11833212B2Linker peptide for constructing fusion proteinAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2021·Granted Dec 5, 2023·1 cites·20 claims
- 0283US11123438B2Linker peptide for constructing fusion proteinAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2016·Granted Sep 21, 2021·6 cites·19 claims
- 0374US2024108743A1Linker peptide for constructing fusion proteinAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2023·Application pending·0 cites
- 0472US11161904B2Anti-PD-1 antibody and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2017·Granted Nov 2, 2021·1 cites·27 claims
- 0570US11884725B2Antibody against TIM-3 and application thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2019·Granted Jan 30, 2024·1 cites·20 claims
- 0670US2022002431A1Bispecific antibody binding to cd20 and cd3 and uses thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2019·Application pending·0 cites
- 0770US2023073411A1Homodimer-type bispecific antibody against her2 and cd3 and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2019·Application pending·0 cites
- 0869US2024254187A1Dual-function protein for lipid and blood glucose regulationAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2024·Application pending·0 cites
- 0968US2022002407A1Homodimer-type bispecific antibody targeting cd19 and cd3, and preparation method therefor and application thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2019·Application pending·0 cites
- 1066US2021371526A1Homodimeric bispecific antibody, preparation method therefor and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2019·Application pending·0 cites
- 1163US2025368752A1Monoclonal antibody against tfpi and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2023·Application pending·0 cites
- 1262US11981718B2Dual-function protein for lipid and blood glucose regulationAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2020·Granted May 14, 2024·0 cites·8 claims
- 1356US2024317857A1Anti-cd3 antibody and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1451US11472863B2Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2017·Granted Oct 18, 2022·0 cites·8 claims
- 1550US11655292B2Anti-human NGF antibodies and methods using sameAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2020·Granted May 23, 2023·0 cites·8 claims
- 1650US2023134182A1Method for efficiently separating and purifying recombinant human coagulate factor viii fc fusion proteinAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2021·Application pending·0 cites
- 1749US2024317862A1Anti-b7-h3 monoclonal antibody and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2022·Application pending·0 cites
- 1848US2022242926A1Fgf21 fc fusion protein, glp-1 fc fusion protein, and combination therapeutic agent comprising same and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2020·Application pending·0 cites
- 1946US2022033476A1Fusion protein of mutated single-chain human coagulation factor viii, preparation method therefor, and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2019·Application pending·0 cites
- 2040US11471513B2Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of sameAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2016·Granted Oct 18, 2022·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when AMPSOURCE BIOPHARMA SHANGHAI INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →